ストックスクリーナーアプリを入手
0.449
16.93%
0.065
アフターアワーズ：
.42
-0.029
-6.46%
前日終値:
$0.384
開ける：
$0.4
24時間の取引高:
594.80K
Relative Volume:
2.41
時価総額：
$13.98M
収益：
$38,000
当期純損益:
$-51.55M
株価収益率:
-0.2338
EPS:
-1.9207
ネットキャッシュフロー:
$-37.07M
1週間 パフォーマンス:
+26.94%
1か月 パフォーマンス:
-53.59%
6か月 パフォーマンス:
-46.03%
1年 パフォーマンス:
-70.65%
1日の値動き範囲:
$0.3902
$0.47
1週間の範囲:
$0.3449
$0.47
52週間の値動き範囲:
$0.3331
$2.88
Senti Biosciences Holdings Inc Stock (SNTI) Company Profile
名前
Senti Biosciences Holdings Inc
セクター
電話
(650) 239-2030
住所
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Holdings Inc
|
0.449 | 11.69M | 38,000 | -51.55M | -37.07M | -1.9207 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Senti Biosciences Holdings Inc Stock (SNTI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-14 | 開始されました | H.C. Wainwright | Buy |
| 2025-06-06 | 開始されました | Laidlaw | Buy |
| 2022-10-07 | 開始されました | Morgan Stanley | Equal-Weight |
Senti Biosciences Holdings Inc (SNTI) 最新ニュース
Senti Biosciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Senti Biosciences Holdings Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Senti Biosciences (NASDAQ:SNTI) to spin off SENTI-202 pipeline to Celadon-backed NewCo via CVRs - kalkine.com.au
SNTI|Senti Biosciences Inc|Price:0.373|Chg%:-0.030 - TradingKey
$Senti Biosciences (SNTI.US)$ - Moomoo
Senti Biosciences Holdings, Inc. SEC Filing (Jul 21, 2026) - Stock Titan
Form 13D/A Senti Biosciences Holdings For: 16 July By Investing.com - Investing.com Nigeria
Form S-3/A Senti Biosciences Holdings Inc For: 16 July - Investing.com Nigeria
Form S-3/A Senti Biosciences Holdings Inc For: 16 July By Investing.com - Investing.com South Africa
Senti Biosciences (SNTI) backer plans merger and $6M funding - Stock Titan
Senti Biosciences to spin off gene therapy unit for CVR - Investing.com
Senti Biosciences Holdings Announces Strategic Spin-Off of Gene-Circuit Pipeline and Plans Focus on Regulator Dial Platform - Quiver Quantitative
Senti Biosciences to Divest Operating Business to Celadon Affiliate; Holders Get Up to $60M CVRs - TradingView
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Te - Yahoo Finance
SNTI Should I Buy - Intellectia AI
Price to sales forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Price to book forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Enterprise value to EBITDA forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Enterprise value to EBIT forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Senti Biosciences Holdings Inc Actuals & Estimates (NASDAQ:SNTI) - TradingView
SNTI Forecast — Price Target — Prediction for 2027 - TradingView
Senti Biosciences (SNTI) registers 15.97M shares tied to May 2026 notes - Stock Titan
Senti Biosciences Inc (SNTI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SNTI Q1 2026 Earnings: Modest EPS Beat Amid Development ProgressEarnings Call Transcript - dars.gov.et
Senti Biosciences Inc (SNTI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
The Radoff-JEC Group Highlights Seer Inc.’s and Chairman and CEO Omid Farokhzad, M.D.’s History of Value Destruction - Business Wire
SNTI Stock Price, Quote & Chart | SENTI BIOSCIENCES HOLDINGS I (NASDAQ:SNTI) - ChartMill
SNTISenti Biosciences Holdings Inc Options - Finviz
Senti Biosciences Inc. (SNTI) Stays Near Key Support Following Modest UptickTake Profit Levels - The Legal Advocate
Senti Biosciences (SNTI) sells $10M notes, outlines up to $60M SENTI-202 CVR - Stock Titan
Senti Biosciences Stock Near $1: FDA Signal and Cash Test Put SNTI Back on Watch - Bez Kabli
Senti Biosciences Inc. Q1 2026 Earnings: Narrowing Losses and Gene Circuitry ProgressCFO Commentary Report - Newser
Senti Bio Advances SENTI-202 to Pivotal Trial With Donor X Selection Strategy - The Clinical Trial Vanguard
Senti Biosciences Holdings, Inc.Common Stock (NQ: SNTI - The Chronicle-Journal
Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure - TipRanks
SNTI Maintained by Chardan Capital -- Price Target Raised to $12 - GuruFocus
Chardan Raises Price Target on Senti Biosciences to $12 From $11, Keeps Buy Rating - Moomoo
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program - Sahm
Senti Biosciences Secures FDA Support for SENTI-202 Donor Selection Strategy in AML - The Clinical Trial Vanguard
Senti Biosciences (NASDAQ: SNTI) flags going concern, lines up $40M convertible note financing - Stock Titan
Senti Biosciences Advances SENTI-202 to Pivotal Phase for AML, Secures $40M Financing, and Reports Reduced Q1 2026 Loss - Minichart
Senti Biosciences 1Q Loss $4.22M >SNTI - Moomoo
Senti Biosciences Advances SENTI-202 With New FDA Support - TipRanks
Senti Bio plans pivotal trial for AML therapy after FDA meeting - Investing.com
Senti Biosciences Holdings announces positive FDA RMAT meeting on registrational clinical and CMC strategy - marketscreener.com
Senti Bio plans pivotal trial for AML therapy after FDA meeting By Investing.com - Investing.com South Africa
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy - TradingView
Senti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia - Quiver Quantitative
Senti Bio (NASDAQ: SNTI) wins FDA RMAT backing and lines up $40M funding - Stock Titan
Senti Biosciences 1Q Loss/Shr 14c >SNTI - Moomoo
SNTI: Q1 2026 featured SENTI-202 clinical progress, reduced net loss, and new $40M financing - TradingView
Senti Biosciences Holdings Inc (SNTI) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):